{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:08:23Z","timestamp":1790885303104,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T00:00:00Z","timestamp":1425513600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13024-015-0001-3","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T15:00:58Z","timestamp":1425481258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice"],"prefix":"10.1186","volume":"10","author":[{"given":"Jin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-wu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,5]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","volume":"9","author":"W Thies","year":"2013","unstructured":"Thies W, Bleiler L, Alzheimer's A. 2013 Alzheimer\u2019s disease facts and figures. Alzheimers Dement: J Alzheimers Assoc. 2013;9:208\u201345.","journal-title":"Alzheimers Dement: J Alzheimers Assoc"},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106\u201318.","journal-title":"Nat Rev Neurol"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrn2620","volume":"10","author":"G Bu","year":"2009","unstructured":"Bu G. Apolipoprotein E and its receptors in Alzheimer\u2019s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10:333\u201344.","journal-title":"Nat Rev Neurosci"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron. 2009;63:287\u2013303.","journal-title":"Neuron"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133.","journal-title":"Science"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"EH Corder","year":"1994","unstructured":"Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell Jr PC, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180\u20134.","journal-title":"Nat Genet"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","volume":"81","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer\u2019s disease: accidental encounters or partners? Neuron. 2014;81:740\u201354.","journal-title":"Neuron"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136.","journal-title":"Science"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ. The molecular pathology of Alzheimer\u2019s disease. Neuron. 1991;6:487\u201398.","journal-title":"Neuron"},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer\u2019s disease. Science. 2010;330:1774.","journal-title":"Science"},{"key":"1_CR11","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2009;106:6820\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR12","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med. 2011;3:89ra57.","journal-title":"Sci Transl Med"},{"key":"1_CR13","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1523\/JNEUROSCI.0887-09.2009","volume":"29","author":"KR Bales","year":"2009","unstructured":"Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci : Off J Soc Neurosci. 2009;29:6771\u20139.","journal-title":"J Neurosci : Off J Soc Neurosci"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1093\/hmg\/dds296","volume":"21","author":"C Cruchaga","year":"2012","unstructured":"Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer\u2019s disease. Hum Mol Genet. 2012;21:4558\u201371.","journal-title":"Hum Mol Genet"},{"key":"1_CR15","doi-asserted-by":"publisher","first-page":"11445","DOI":"10.1523\/JNEUROSCI.1972-08.2008","volume":"28","author":"DR Riddell","year":"2008","unstructured":"Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci : Off J Soc Neurosci. 2008;28:11445\u201353.","journal-title":"J Neurosci : Off J Soc Neurosci"},{"key":"1_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2009.05.011","volume":"32","author":"PM Sullivan","year":"2011","unstructured":"Sullivan PM, Han B, Liu F, Mace BE, Ervin JF, Wu S, et al. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging. 2011;32:791\u2013801.","journal-title":"Neurobiol Aging"},{"key":"1_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-013-1086-9","volume":"125","author":"M Shinohara","year":"2013","unstructured":"Shinohara M, Petersen RC, Dickson DW, Bu G. Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol. 2013;125:535\u201347.","journal-title":"Acta Neuropathol"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.mcn.2007.01.011","volume":"34","author":"DR Riddell","year":"2007","unstructured":"Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer\u2019s disease. Mol Cell Neurosci. 2007;34:621\u20138.","journal-title":"Mol Cell Neurosci"},{"key":"1_CR19","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.neurobiolaging.2009.07.005","volume":"32","author":"T Vanmierlo","year":"2011","unstructured":"Vanmierlo T, Rutten K, Dederen J, Bloks VW, van Vark-van der Zee LC, Kuipers F, et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol Aging. 2011;32:1262\u201372.","journal-title":"Neurobiol Aging"},{"key":"1_CR20","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1126\/science.1217697","volume":"335","author":"PE Cramer","year":"2012","unstructured":"Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science. 2012;335:1503\u20136.","journal-title":"Science"},{"key":"1_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0005-2760(87)90295-5","volume":"917","author":"RE Pitas","year":"1987","unstructured":"Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987;917:148\u201361.","journal-title":"Biochim Biophys Acta"},{"key":"1_CR22","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1172\/JCI6172","volume":"103","author":"C Knouff","year":"1999","unstructured":"Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103:1579\u201386.","journal-title":"J Clin Invest"},{"key":"1_CR23","doi-asserted-by":"publisher","first-page":"17972","DOI":"10.1074\/jbc.272.29.17972","volume":"272","author":"PM Sullivan","year":"1997","unstructured":"Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272:17972\u201380.","journal-title":"J Biol Chem"},{"key":"1_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1172\/JCI2673","volume":"102","author":"PM Sullivan","year":"1998","unstructured":"Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest. 1998;102:130\u20135.","journal-title":"J Clin Invest"},{"key":"1_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1006\/nbdi.1996.0023","volume":"3","author":"PT Xu","year":"1996","unstructured":"Xu PT, Schmechel D, Rothrock-Christian T, Burkhart DS, Qiu HL, Popko B, et al. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis. 1996;3:229\u201345.","journal-title":"Neurobiol Dis"},{"key":"1_CR26","doi-asserted-by":"publisher","first-page":"12382","DOI":"10.1128\/JVI.75.24.12382-12392.2001","volume":"75","author":"MA Passini","year":"2001","unstructured":"Passini MA, Wolfe JH. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J Virol. 2001;75:12382\u201392.","journal-title":"J Virol"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/ejn.12126","volume":"37","author":"JY Kim","year":"2013","unstructured":"Kim JY, Ash RT, Ceballos-Diaz C, Levites Y, Golde TE, Smirnakis SM, et al. Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo. Eur J Neurosci. 2013;37:1203\u201320.","journal-title":"Eur J Neurosci"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"e67680","DOI":"10.1371\/journal.pone.0067680","volume":"8","author":"P Chakrabarty","year":"2013","unstructured":"Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, et al. Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS One. 2013;8:e67680.","journal-title":"PLoS One"},{"key":"1_CR29","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/jamaneurol.2013.396","volume":"70","author":"AJ Hanson","year":"2013","unstructured":"Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol. 2013;70:972\u201380.","journal-title":"JAMA Neurol"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"41774","DOI":"10.1074\/jbc.M112.407957","volume":"287","author":"KL Youmans","year":"2012","unstructured":"Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287:41774\u201386.","journal-title":"J Biol Chem"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1074\/jbc.M112.442103","volume":"288","author":"LM Tai","year":"2013","unstructured":"Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, et al. Levels of soluble apolipoprotein E\/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem. 2013;288:5914\u201326.","journal-title":"J Biol Chem"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1172\/JCI36663","volume":"118","author":"R Deane","year":"2008","unstructured":"Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002\u201313.","journal-title":"J Clin Invest"},{"key":"1_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.med.47.1.387","volume":"47","author":"AD Roses","year":"1996","unstructured":"Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer\u2019s disease. Annu Rev Med. 1996;47:387\u2013400.","journal-title":"Annu Rev Med"},{"key":"1_CR34","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1172\/JCI24761","volume":"115","author":"L Bertram","year":"2005","unstructured":"Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest. 2005;115:1449\u201357.","journal-title":"J Clin Invest"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1073\/pnas.050004797","volume":"97","author":"DM Holtzman","year":"2000","unstructured":"Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2000;97:2892\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0896-6273(03)00850-X","volume":"41","author":"RB DeMattos","year":"2004","unstructured":"DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41:193\u2013202.","journal-title":"Neuron"},{"key":"1_CR37","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI6179","volume":"103","author":"DM Holtzman","year":"1999","unstructured":"Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer\u2019s disease. J Clin Invest. 1999;103:R15\u201321.","journal-title":"J Clin Invest"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1006\/nbdi.2002.0483","volume":"9","author":"AM Fagan","year":"2002","unstructured":"Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2002;9:305\u201318.","journal-title":"Neurobiol Dis"},{"key":"1_CR39","doi-asserted-by":"publisher","first-page":"212ra161","DOI":"10.1126\/scitranslmed.3007000","volume":"5","author":"E Hudry","year":"2013","unstructured":"Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med. 2013;5:212ra161.","journal-title":"Sci Transl Med"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tibs.2006.06.008","volume":"31","author":"DM Hatters","year":"2006","unstructured":"Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci. 2006;31:445\u201354.","journal-title":"Trends Biochem Sci"},{"key":"1_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H","volume":"49","author":"MJ LaDu","year":"1997","unstructured":"LaDu MJ, Lukens JR, Reardon CA, Getz GS. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. J Neurosci Res. 1997;49:9\u201318.","journal-title":"J Neurosci Res"},{"key":"1_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-1326-9-2","volume":"9","author":"LM Tai","year":"2014","unstructured":"Tai LM, Mehra S, Shete V, Estus S, Rebeck GW, Bu G, et al. Soluble apoE\/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener. 2014;9:2.","journal-title":"Mol Neurodegener"},{"key":"1_CR43","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.jcbfm.9600419","volume":"27","author":"RD Bell","year":"2007","unstructured":"Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer\u2019s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb blood Flow Metab : Off J Int Soc Cereb Blood Flow Metab. 2007;27:909\u201318.","journal-title":"J Cereb blood Flow Metab : Off J Int Soc Cereb Blood Flow Metab"},{"key":"1_CR44","doi-asserted-by":"publisher","first-page":"34144","DOI":"10.1074\/jbc.M110.108100","volume":"285","author":"JJ Donkin","year":"2010","unstructured":"Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein\/presenilin 1 mice. J Biol Chem. 2010;285:34144\u201354.","journal-title":"J Biol Chem"},{"key":"1_CR45","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","volume":"58","author":"Q Jiang","year":"2008","unstructured":"Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681\u201393.","journal-title":"Neuron"},{"key":"1_CR46","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jmb.2006.06.080","volume":"361","author":"DM Hatters","year":"2006","unstructured":"Hatters DM, Zhong N, Rutenber E, Weisgraber KH. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol. 2006;361:932\u201344.","journal-title":"J Mol Biol"},{"key":"1_CR47","doi-asserted-by":"publisher","first-page":"13125","DOI":"10.1523\/JNEUROSCI.1937-12.2012","volume":"32","author":"NF Fitz","year":"2012","unstructured":"Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, et al. Abca1 deficiency affects Alzheimer\u2019s disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J Neurosci : Off J Soc Neurosci. 2012;32:13125\u201336.","journal-title":"J Neurosci : Off J Soc Neurosci"},{"key":"1_CR48","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S1046-2023(02)00220-7","volume":"28","author":"S Zolotukhin","year":"2002","unstructured":"Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites Jr TJ, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods. 2002;28:158\u201367.","journal-title":"Methods"},{"key":"1_CR49","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.4049\/jimmunol.0903382","volume":"184","author":"P Chakrabarty","year":"2010","unstructured":"Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, et al. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol. 2010;184:5333\u201343.","journal-title":"J Immunol"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1326-7-39","volume":"7","author":"P Das","year":"2012","unstructured":"Das P, Verbeeck C, Minter L, Chakrabarty P, Felsenstein K, Kukar T, et al. Transient pharmacologic lowering of Abeta production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener. 2012;7:39.","journal-title":"Mol Neurodegener"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-015-0001-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13024-015-0001-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-015-0001-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-015-0001-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:44:25Z","timestamp":1630572265000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-015-0001-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,5]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1"],"URL":"https:\/\/doi.org\/10.1186\/s13024-015-0001-3","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,5]]},"assertion":[{"value":"23 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"6"}}